AI can help to tailor drugs for Africa — but Africans should lead the way
Authors:
- Gemma TuronGTGemma Turon
- Mathew NjorogeMNMathew Njoroge
- Mwila MulubwaMMMwila Mulubwa
- Miquel Duran-FrigolaMDMiquel Duran-Frigola
- Kelly ChibaleKCKelly Chibale
- 9 April 2024
- journal article
- editorial
- Published by Springer Nature in Nature
- Vol. 628 (8007) , 265-267
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Foundation model for cancer imaging biomarkersNature Machine Intelligence, 2024
- Addressing Ancestry and Sex Bias in PharmacogenomicsAnnual Review of Pharmacology and Toxicology, 2024
- Accurate proteome-wide missense variant effect prediction with AlphaMissenseScience, 2023
- Evidence-based Medicine and Mechanistic Evidence: The Case of the Failed Rollout of Efavirenz in ZimbabweThe Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine, 2023
- Transfer learning for medical image classification: a literature reviewBMC Medical Imaging, 2022
- Warfarin Dosing in Patients With CYP2C9*5 Variant AllelesClinical Pharmacology & Therapeutics, 2022
- A Review of Clinical Pharmacogenetics Studies in African PopulationsPersonalized Medicine, 2020
- Efavirenz and the CNS: what we already know and questions that need to be answeredJournal of Antimicrobial Chemotherapy, 2015
- Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir DosingClinical Pharmacology & Therapeutics, 2012
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003